Respiratory failure & ventilation

Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a bayesian post-hoc analysis of the NIVAS trial

Crit CarePublished Secondary analysis of the NIVAS randomised trial

Primary result · Day-7 reintubationResult — go to the resultPosterior median OR 0.59 95% CrI 0.37–0.95

Authors' conclusion

This Bayesian trial re-analysis indicates that NIV has a high probability of achieving a clinically meaningful reduction in day 7 reintubation, even under pessimistic prior beliefs.

Study context

Population
Patients with acute respiratory failure following abdominal surgery
Participants
293 patients
Comparison
Noninvasive ventilation (NIV) vs conventional oxygen therapy
Primary endpoint
Reintubation
Follow-up
Day 7
Methodological detailspost-hoc Bayesian reanalysis, prospectively registered, multicentre
  • Post-hoc Bayesian reanalysis
  • Prospectively registered
  • Multicentre

Primary result

Day-7 reintubation

Posterior median OR

0.59

95% CrI 0.37–0.95

NIV vs Oxygen therapy
posterior median OR 0.59 (95% CrI 0.37–0.95)

As reported in the abstract

Posterior median OR, pessimistic prior
0.64 (95% CrI 0.40 to 1.00)
Posterior probability NIV superior to oxygen therapy, pessimistic to enthusiastic priors
96 to 99%
Probability of benefit beyond absolute risk reduction (ARR) ≥ 5%
77 to 93%

Secondary outcomes

Day-30 mortality

Posterior median OR, minimally informative prior
0.63 (95% CrI 0.32 to 1.31)
Posterior median OR, skeptical prior
0.79 (95% CrI 0.48 to 1.29)
Probability of NIV superiority
82 to 90%

Original publication

Effect of noninvasive ventilation on tracheal reintubation among patients with hypoxemic respiratory failure following abdominal surgery: a bayesian post-hoc analysis of the NIVAS trial. Crit Care. Published 10 December 2025. doi:10.1186/s13054-025-05795-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.